{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.55","value":"63.4"},{"groupId":"OG001","spread":"25.05","value":"59.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"322"},{"groupId":"OG001","value":"316"}],"units":"Participants"}],"title":"Global Health Status - Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"18.28","value":"-1.1"},{"groupId":"OG001","spread":"23.21","value":"2.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"244"},{"groupId":"OG001","value":"249"}],"units":"Participants"}],"title":"Global Health Status - Week 4"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.73","value":"-0.5"},{"groupId":"OG001","spread":"23.55","value":"3.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"159"},{"groupId":"OG001","value":"204"}],"units":"Participants"}],"title":"Global Health Status - Week 10"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.59","value":"3.6"},{"groupId":"OG001","spread":"24.68","value":"3.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"117"},{"groupId":"OG001","value":"132"}],"units":"Participants"}],"title":"Global Health Status - Week 16"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.02","value":"2.6"},{"groupId":"OG001","spread":"24.44","value":"5.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"103"},{"groupId":"OG001","value":"67"}],"units":"Participants"}],"title":"Global Health Status - Week 20"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"25.78","value":"1.9"},{"groupId":"OG001","spread":"26.19","value":"2.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"106"},{"groupId":"OG001","value":"36"}],"units":"Participants"}],"title":"Global Health Status - Week 24"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.14","value":"-0.9"},{"groupId":"OG001","spread":"28.81","value":"-1.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"89"},{"groupId":"OG001","value":"10"}],"units":"Participants"}],"title":"Global Health Status - Week 36"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.72","value":"0.5"},{"groupId":"OG001","spread":"17.35","value":"2.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"62"},{"groupId":"OG001","value":"3"}],"units":"Participants"}],"title":"Global Health Status - Week 48"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"24.11","value":"7.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"56"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"Global Health Status - Week 60"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"27.04","value":"2.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"47"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"Global Health Status - Week 72"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"24.40","value":"8.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"Global Health Status - Week 84"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"26.86","value":"3.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"Global Health Status - Week 96"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"37.51","value":"4.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"Global Health Status - Week 108"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"28.46","value":"-20.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"Global Health Status - Week 120"},{"categories":[{"measurements":[{"comment":"Insufficient number of participants to calculate SD.","groupId":"OG000","spread":"NA","value":"-16.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"Global Health Status - Week 144"},{"categories":[{"measurements":[{"comment":"Insufficient number of participants to calculate SD.","groupId":"OG000","spread":"NA","value":"-16.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"Global Health Status - Week 156"},{"categories":[{"measurements":[{"comment":"Insufficient number of participants to calculate SD.","groupId":"OG000","spread":"NA","value":"0.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"Global Health Status - Week 168"},{"categories":[{"measurements":[{"comment":"Insufficient number of participants to calculate SD.","groupId":"OG000","spread":"NA","value":"-8.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"Global Health Status - Week 180"},{"categories":[{"measurements":[{"comment":"Insufficient number of participants to calculate SD.","groupId":"OG000","spread":"NA","value":"-16.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"Global Health Status - Week 192"}],"denoms":[{"counts":[{"groupId":"OG000","value":"349"},{"groupId":"OG001","value":"357"}],"units":"Participants"}],"description":"The EORTC QLQ-C30 is a questionnaire used to assess the quality of life in cancer patients. It includes a global health status score, which is measured on a 4-point Likert scale: 1 = not at all, 2 = a little, 3 = quite a bit, and 4 = very much. Responses are combined and converted to scores ranging from 0 to 100. A high score for global health status or health-related quality of life (HRQoL) indicates a high overall HRQoL.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received Nivolumab 1 mg/kg plus Ipilimumab 3 mg/kg every three weeks (Q3W) for up to 4 doses followed by Nivolumab monotherapy 480 mg every 4 weeks (Q4W) - Primary Study","id":"OG000","title":"Treatment 1"},{"description":"Participants received Standard of Care treatment every three weeks (Q3W) for up to 6 cycles - Primary Study","id":"OG001","title":"Treatment 2"}],"paramType":"MEAN","populationDescription":"All Randomized Participants - Primary Study","reportingStatus":"POSTED","timeFrame":"At Baseline, Week 4, Week 10, Week 16, Week 20, Week 24, Week 36, Week 48, Week 60, Week 72, Week 84, Week 96, Week 108, Week 120, Week 144, Week 156, Week 168, Week 180 and Week 192","title":"Change From Baseline in the European Organization for Research and Treatment of Care Quality-of-Life Questionnaire (EORTC QLQ-C30) Global Health Status Score in All Randomized Participants for Primary Study","type":"SECONDARY","unitOfMeasure":"Score on a Scale"}